Sodium hyaluronate + placebo injection

Phase 3Terminated

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Symptomatic Hip Osteoarthritis

Conditions

Symptomatic Hip Osteoarthritis

Trial Timeline

Jan 1, 2005 → Mar 1, 2007

NCT ID

NCT00330135

About Sodium hyaluronate + placebo injection

Sodium hyaluronate + placebo injection is a phase 3 stage product being developed by Daiichi Sankyo for Symptomatic Hip Osteoarthritis. The current trial status is terminated. This product is registered under clinical trial identifier NCT00330135. Target conditions include Symptomatic Hip Osteoarthritis.

What happened to similar drugs?

3 of 16 similar drugs in Symptomatic Hip Osteoarthritis were approved

Approved (3) Terminated (3) Active (10)

🔄ISV-305Sun PharmaceuticalPhase 3

🔄rabeprazole sodium + PlaceboEisaiPhase 3

🔄Esomeprazole + Matching placeboAstraZenecaPhase 3

🔄Pasireotide + OctreotideNovartisPhase 3

✅valsartanNovartisApproved

🔄Apixaban + Standard of carePfizerPhase 3

❌Azithromycin plus chloroquinePfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00330135	Phase 3	Terminated	Jan 1, 2005	Mar 1, 2007	Symptomatic Hip Osteoarthritis

Competing Products

20 competing products in Symptomatic Hip Osteoarthritis

See all competitors

Product	Company	Stage	Hype Score
ISV-305	Sun Pharmaceutical	Phase 3	40
rabeprazole sodium + Placebo	Eisai	Phase 3	40
Verinurad + Febuxostat + Dapagliflozin	AstraZeneca	Phase 2	35
RDEA3170 + Febuxostat + Benzbromarone	AstraZeneca	Phase 1/2	32
Esomeprazole + Matching placebo	AstraZeneca	Phase 3	40
DFV890 + Placebo	Novartis	Phase 2	35
Omalizumab + Omalizumab + Placebo	Novartis	Phase 2	35
Pasireotide + Octreotide	Novartis	Phase 3	40
Tegaserod	Novartis	Phase 2	35
valsartan	Novartis	Approved	43
Atorvastatin - Cholestyramine - Sitosterol	Pfizer	Pre-clinical	26
Epoetin biosimilar	Pfizer	Pre-clinical	26
Apixaban + Standard of care	Pfizer	Phase 3	40
Azithromycin plus chloroquine	Pfizer	Phase 3	32
Mavacamten	Bristol Myers Squibb	Approved	50
Aficamten + Placebo	Sanofi	Phase 3	44
Vandetanib 300 mg	Sanofi	Pre-clinical	26
REGN7508 + Acetylsalicylic Acid (ASA) + Placebo	Regeneron Pharmaceuticals	Phase 3	47
Rivaroxaban + Placebo	Bayer	Phase 3	37
Droxidopa capsules + Placebo capsules	Lundbeck	Approved	40